Associations of Urine Epidermal Growth Factor With Kidney and Cardiovascular Outcomes in Individuals With CKD in SPRINT

Introduction: Urine epidermal growth factor (uEGF) has been found to be inversely associated with kidney function loss, whereas its associations with cardiovascular disease (CVD) and mortality have not been studied. Methods: We measured baseline uEGF levels among 2346 Systolic Blood Pressure Interve...

Full description

Saved in:
Bibliographic Details
Main Authors: Merve Postalcioglu, Ronit Katz, Simon B. Ascher, Trenton Hall, Pranav S. Garimella, Stein I. Hallan, Joachim H. Ix, Michael G. Shlipak
Format: Article
Language:English
Published: Elsevier 2024-11-01
Series:Kidney International Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S246802492401876X
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849336033633632256
author Merve Postalcioglu
Ronit Katz
Simon B. Ascher
Trenton Hall
Pranav S. Garimella
Stein I. Hallan
Joachim H. Ix
Michael G. Shlipak
author_facet Merve Postalcioglu
Ronit Katz
Simon B. Ascher
Trenton Hall
Pranav S. Garimella
Stein I. Hallan
Joachim H. Ix
Michael G. Shlipak
author_sort Merve Postalcioglu
collection DOAJ
description Introduction: Urine epidermal growth factor (uEGF) has been found to be inversely associated with kidney function loss, whereas its associations with cardiovascular disease (CVD) and mortality have not been studied. Methods: We measured baseline uEGF levels among 2346 Systolic Blood Pressure Intervention Trial (SPRINT) participants with an estimated glomerular filtration rate (eGFR) < 60 ml/min per 1.73 m2. A linear mixed-effects model was used to investigate the associations of uEGF with the annual eGFR change; Cox proportional hazards regression models were used to analyze its associations with the ≥30% eGFR decline, CVD, and all-cause mortality outcomes. To account for the competing risk of death, the Fine and Gray method was utilized for acute kidney injury (AKI) and end-stage kidney disease (ESKD) outcomes. Results: At baseline, the study participants had mean age of 73 ± 9 years, mean eGFR of 46 ± 11 ml/min per 1.73 m2, and median urine albumin-to-creatinine ratio (UACR) of 15 mg/g (interquartile range: 7–49). In the multivariable-adjusted analysis including baseline urine albumin and eGFR, each 50% lower uEGF concentration was associated with 0.74% (95% confidence interval [CI]: 0.29–1.19) per year faster decline in eGFR and 1.17 times higher risk of ≥30% eGFR decline (95% CI: 1.00–1.36). Lower uEGF concentrations were found to be associated with increased risks of ESKD, AKI, CVD, and all-cause mortality; however, these associations did not reach statistical significance when the models were controlled for baseline urine albumin and eGFR. Conclusion: Among hypertensive adults with chronic kidney disease (CKD), lower baseline uEGF concentration was associated with faster eGFR decline independent of baseline albuminuria and eGFR; but not with ESKD, AKI, CVD, and all-cause mortality.
format Article
id doaj-art-18ae7447d6d84b2c88ee8a53750eeafc
institution Kabale University
issn 2468-0249
language English
publishDate 2024-11-01
publisher Elsevier
record_format Article
series Kidney International Reports
spelling doaj-art-18ae7447d6d84b2c88ee8a53750eeafc2025-08-20T03:45:06ZengElsevierKidney International Reports2468-02492024-11-019113167317610.1016/j.ekir.2024.08.004Associations of Urine Epidermal Growth Factor With Kidney and Cardiovascular Outcomes in Individuals With CKD in SPRINTMerve Postalcioglu0Ronit Katz1Simon B. Ascher2Trenton Hall3Pranav S. Garimella4Stein I. Hallan5Joachim H. Ix6Michael G. Shlipak7Kidney Health Research Collaborative, Veterans Affairs San Francisco Healthcare System and University of California San Francisco, San Francisco, California, USADepartment of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USAKidney Health Research Collaborative, Veterans Affairs San Francisco Healthcare System and University of California San Francisco, San Francisco, California, USA; Division of Hospital Medicine, Department of Medicine, University of California Davis, Sacramento, California, USAKidney Health Research Collaborative, Veterans Affairs San Francisco Healthcare System and University of California San Francisco, San Francisco, California, USADivision of Nephrology and Hypertension, Department of Medicine, University of California San Diego, San Diego, California, USADepartment of Nephrology, St Olav's Hospital and Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, NorwayDivision of Nephrology and Hypertension, Department of Medicine, University of California San Diego, San Diego, California, USA; Nephrology Section, Veterans Affairs San Diego Healthcare System, San Diego, California, USAKidney Health Research Collaborative, Veterans Affairs San Francisco Healthcare System and University of California San Francisco, San Francisco, California, USA; Correspondence: Michael Shlipak, University of California, 4150 Clement Street, Building 2, Room 455C, San Francisco, California, 94121, USA.Introduction: Urine epidermal growth factor (uEGF) has been found to be inversely associated with kidney function loss, whereas its associations with cardiovascular disease (CVD) and mortality have not been studied. Methods: We measured baseline uEGF levels among 2346 Systolic Blood Pressure Intervention Trial (SPRINT) participants with an estimated glomerular filtration rate (eGFR) < 60 ml/min per 1.73 m2. A linear mixed-effects model was used to investigate the associations of uEGF with the annual eGFR change; Cox proportional hazards regression models were used to analyze its associations with the ≥30% eGFR decline, CVD, and all-cause mortality outcomes. To account for the competing risk of death, the Fine and Gray method was utilized for acute kidney injury (AKI) and end-stage kidney disease (ESKD) outcomes. Results: At baseline, the study participants had mean age of 73 ± 9 years, mean eGFR of 46 ± 11 ml/min per 1.73 m2, and median urine albumin-to-creatinine ratio (UACR) of 15 mg/g (interquartile range: 7–49). In the multivariable-adjusted analysis including baseline urine albumin and eGFR, each 50% lower uEGF concentration was associated with 0.74% (95% confidence interval [CI]: 0.29–1.19) per year faster decline in eGFR and 1.17 times higher risk of ≥30% eGFR decline (95% CI: 1.00–1.36). Lower uEGF concentrations were found to be associated with increased risks of ESKD, AKI, CVD, and all-cause mortality; however, these associations did not reach statistical significance when the models were controlled for baseline urine albumin and eGFR. Conclusion: Among hypertensive adults with chronic kidney disease (CKD), lower baseline uEGF concentration was associated with faster eGFR decline independent of baseline albuminuria and eGFR; but not with ESKD, AKI, CVD, and all-cause mortality.http://www.sciencedirect.com/science/article/pii/S246802492401876Xcardiovascular diseasechronic kidney diseaseepidermal growth factorkidney tubule biomarkermortalitySPRINT
spellingShingle Merve Postalcioglu
Ronit Katz
Simon B. Ascher
Trenton Hall
Pranav S. Garimella
Stein I. Hallan
Joachim H. Ix
Michael G. Shlipak
Associations of Urine Epidermal Growth Factor With Kidney and Cardiovascular Outcomes in Individuals With CKD in SPRINT
Kidney International Reports
cardiovascular disease
chronic kidney disease
epidermal growth factor
kidney tubule biomarker
mortality
SPRINT
title Associations of Urine Epidermal Growth Factor With Kidney and Cardiovascular Outcomes in Individuals With CKD in SPRINT
title_full Associations of Urine Epidermal Growth Factor With Kidney and Cardiovascular Outcomes in Individuals With CKD in SPRINT
title_fullStr Associations of Urine Epidermal Growth Factor With Kidney and Cardiovascular Outcomes in Individuals With CKD in SPRINT
title_full_unstemmed Associations of Urine Epidermal Growth Factor With Kidney and Cardiovascular Outcomes in Individuals With CKD in SPRINT
title_short Associations of Urine Epidermal Growth Factor With Kidney and Cardiovascular Outcomes in Individuals With CKD in SPRINT
title_sort associations of urine epidermal growth factor with kidney and cardiovascular outcomes in individuals with ckd in sprint
topic cardiovascular disease
chronic kidney disease
epidermal growth factor
kidney tubule biomarker
mortality
SPRINT
url http://www.sciencedirect.com/science/article/pii/S246802492401876X
work_keys_str_mv AT mervepostalcioglu associationsofurineepidermalgrowthfactorwithkidneyandcardiovascularoutcomesinindividualswithckdinsprint
AT ronitkatz associationsofurineepidermalgrowthfactorwithkidneyandcardiovascularoutcomesinindividualswithckdinsprint
AT simonbascher associationsofurineepidermalgrowthfactorwithkidneyandcardiovascularoutcomesinindividualswithckdinsprint
AT trentonhall associationsofurineepidermalgrowthfactorwithkidneyandcardiovascularoutcomesinindividualswithckdinsprint
AT pranavsgarimella associationsofurineepidermalgrowthfactorwithkidneyandcardiovascularoutcomesinindividualswithckdinsprint
AT steinihallan associationsofurineepidermalgrowthfactorwithkidneyandcardiovascularoutcomesinindividualswithckdinsprint
AT joachimhix associationsofurineepidermalgrowthfactorwithkidneyandcardiovascularoutcomesinindividualswithckdinsprint
AT michaelgshlipak associationsofurineepidermalgrowthfactorwithkidneyandcardiovascularoutcomesinindividualswithckdinsprint